San­i­fit touts pos­i­tive PhI­Ib da­ta; RE­GENXBIO li­cens­es Clear­side Bio­med­ical tech

→ Rare dis­ease biotech San­i­fit — which in June, raised near­ly $81 mil­lion in Spain’s largest-ever pri­vate biotech fundraise — has an­nounced that its in­ter­na­tion­al Phase IIb CaLIP­SO study of SNF472 met its pri­ma­ry end­point. The tri­al stud­ied pa­tients with end-stage kid­ney dis­ease (ES­KD) on he­modial­y­sis and demon­strat­ed a re­duc­tion in coro­nary artery cal­ci­um (CAC) vol­ume in pa­tients treat­ed with SNF472 ver­sus place­bo. De­tailed da­ta will be pre­sent­ed at a med­ical con­fer­ence.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.